Details for Patent: 7,795,428

Title:	Dipeptidyl peptidase inhibitors
Abstract:	Compounds are provided for use with DPP-IV of the formula: ##STR00001## Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
Inventor(s):	Feng; Jun (Carlsbad, CA), Gwaltney; Stephen L. (Escondido, CA), Stafford; Jeffrey Alan (San Diego, CA), Zhang; Zhiyuan (San Diego, CA), Elder; Bruce (Wynantskill, NY), Isbester; Paul (Castleton, NY), Palmer; Grant (Clifton Park, NY), Salsbury; Jonathan S. (Albany, NY), Ulysse; Luckner (Albany, NY)
Assignee:	Takeda Pharmaceutical Company Limited (Osaka, JP)
Filing Date:	Aug 07, 2007
Application Number:	11/835,295
Claims:	1. A compound of the formula ##STR00064## or stereoisomersor pharmaceutically acceptable salts thereof. 2. The compound according to claim 1, wherein the compound is present as a mixture of stereoisomers. 3. The compound according to claim 1, wherein the compound is present as a single stereoisomer. 4. A compound of the formula ##STR00065## or pharmaceutically acceptable salts thereof. 5. A compound of the formula ##STR00066## wherein the compound is present as a succinate salt, or stereoisomers thereof. 6. The compound according to claim 5, wherein the compound is present as a mixture of stereoisomers. 7. The compound according to claim 6, wherein the compound is present as a single stereoisomer. 8. A compound of the formula ##STR00067## wherein the compound is present as a succinate salt. 9. A pharmaceutical composition comprising, as an active ingredient, a compound of the formula ##STR00068## or stereoisomersor pharmaceutically acceptable salts thereof; and one or more pharmaceutically acceptable excipients. 10. The pharmaceutical composition according to claim 9, wherein the composition is a solid formulation adapted for oral administration. 11. The pharmaceutical composition according to claim 9, wherein the composition is a tablet. 12. The pharmaceutical composition according to claim 9, wherein the composition is a liquid formulation adapted for oral administration. 13. The pharmaceutical composition according to claim 9, wherein the composition is a liquid formulation adapted for parenteral administration. 14. The pharmaceutical composition according to claim 9, wherein the composition is adapted for administration by a route selected from the group consisting of orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery, subcutaneously, intraadiposally, intraarticularly, and intrathecally. 15. A pharmaceutical composition comprising, as an active ingredient, a compound of the formula ##STR00069## wherein the compound is present as a succinate salt; and one or more pharmaceutically acceptable excipients. 16. The pharmaceutical composition according to claim 15, wherein the composition is a solid formulation adapted for oral administration. 17. The pharmaceutical composition according to claim 15, wherein the composition is a tablet. 18. The pharmaceutical composition according to claim 15, wherein the composition is a liquid formulation adapted for oral administration. 19. The pharmaceutical composition according to claim 15, wherein the composition is a liquid formulation adapted for parenteral administration. 20. The pharmaceutical composition according to claim 15, wherein the composition is adapted for administration by a route selected from the group consisting of orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery, subcutaneously, intraadiposally, intraarticularly, and intrathecally. 21. A kit comprising: a compound of the formula ##STR00070## or stereoisomers or pharmaceutically acceptable salts thereof; and instructions which comprise one or more forms of information selected from the group consisting of indicating a disease state for which the compound is to be administered selected from the group consisting of diabetes, breast cancer and rheumatoid arthritis, storage information for the compound, dosing information and instructions regarding how to administer the compound. 22. The kit according to claim 21, wherein the kit comprises the compound in a multiple dose form. 23. A kit comprising: a compound of the formula ##STR00071## wherein the compound is present as a succinate salt; and instructions which comprise one or more forms of information selected from the group consisting of indicating a disease state for which the compound is to be administered selected from the group consisting of diabetes, breast cancer and rheumatoid arthritis, storage information for the compound, dosing information and instructions regarding how to administer the compound. 24. The kit according to claim 23, wherein the kit comprises the compound in a multiple dose form. 25. An article of manufacture comprising: a compound of the formula ##STR00072## or stereoisomers or pharmaceutically acceptable salts thereof; and packaging materials. 26. The article of manufacture of claim 25, wherein the packaging material comprises a container for housing the compound. 27. The article of manufacture of claim 26, wherein the container comprises a label indicating one or more members of the group consisting of a disease state for which the compound is to be administered selected from the group consisting of diabetes, breast cancer and rheumatoid arthritis, storage information, dosing information and/or instructions regarding how to administer the composition. 28. The article of manufacture of claim 25, wherein the article of manufacture comprises the compound in a multiple dose form. 29. An article of manufacture comprising: a compound of the formula ##STR00073## wherein the compound is present as a succinate salt; and packaging materials. 30. The article of manufacture of claim 29, wherein the packaging material comprises a container for housing the compound. 31. The article of manufacture of claim 30, wherein the container comprises a label indicating one or more members of the group consisting of a disease state for which the compound is to be administered selected from the group consisting of diabetes, breast cancer and rheumatoid arthritis, storage information, dosing information and/or instructions regarding how to administer the composition. 32. The article of manufacture of claim 29, wherein the article of manufacture comprises the compound in a multiple dose form. 33. A method of treating type II diabetes in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of the formula ##STR00074## or stereoisomers or pharmaceutically acceptable salts thereof. 34. A method of treating type I diabetes in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of the formula ##STR00075## or stereoisomers or pharmaceutically acceptable salts thereof. 35. A method of treating breast cancer in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to claim 1. 36. A method of treating rheumatoid arthritis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to claim 1. 37. A method of treating type II diabetes in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to claim 8. 38. A method of treating type I diabetes in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to claim 8. 39. A method of treating breast cancer in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to claim 8. 40. A method of treating rheumatoid arthritis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to claim 8. 41. A process for producing a product of the formula ##STR00076## the process comprising the steps of: (i) contacting a compound of the formula A ##STR00077## wherein Hal is halogen; with a compound of the formula B ##STR00078## wherein LG is a leaving group; to produce a compound of the formula C ##STR00079## (ii) contacting the compound of formula C with a compound of formula D H.sub.3C-LG' D wherein LG' is a leaving group; to produce a compound of the formula E; ##STR00080## (iii) contacting the compound of formula E with a compound of formula ##STR00081## to produce the product. 42. The process of claim 41, wherein Hal is selected from the group consisting of Br, Cl and F. 43. The process of claim 41, wherein the leaving group LG' is selected from the group consisting of Br, Cl and I. 44. The process of claim 41, wherein step (ii) further comprises the addition of a base. 45. The process of claim 44, wherein the base is potassium carbonate. 46. The process of claim 41, wherein product E is further purified before being subjected to step (iii). 47. The process of claim 46, wherein the purification of product E is performed by solvent washes and/or by chromatography. 48. The process of claim 41, wherein step iii) further comprises a purification step of washing of the product with organic solvents or mixture of solvents and/or by column chromatography. 49. The process of claim 41, further comprising the step of reacting the product with an acid to produce an acid addition salt. 50. The process of claim 49, wherein the acid addition salt is a hydrochloric acid salt. 51. The process of claim 49, wherein the acid addition salt is a succinate salt. 52. The process of claim 49, wherein the acid addition salt is a methanesulfonate salt. 53. The process of claim 41, wherein the product is present in a mixture of stereoisomers. 54. The process of claim 41, wherein the product is present as a single stereoisomer. 55. A process for producing a product of the formula ##STR00082## the process comprising the steps of (i) admixing 6-chloro-1H-pyrimidine-2,4-dione with an aryl halide of the formula ##STR00083## wherein Hal is Br, Cl, or I, to produce a compound of the formula ##STR00084## (ii) alkylating the above product with a methyl halide to form a compound of the formula ##STR00085## (iii) condensing the above product with a compound of the formula ##STR00086## 56. The process of claim 55, further comprising the step of reacting the product with an acid to produce an acid addition salt. 57. The process of claim 56, wherein the acid addition salt is a hydrochloric acid salt. 58. The process of claim 56, wherein the acid addition salt is a succinate salt. 59. The process of claim 56, wherein the acid addition salt is a methanesulfonate salt.